Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 3 3Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 4 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 2Metastatic Castration Resistant Prostate Cancer (mCRPC) 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Lutetium-177 × Genitourinary × Clear all
NCT05849298 2026-05-27

PSMACare

Novartis

Phase 2 Active not recruiting
49 enrolled
Genitourinary

Prostatic Neoplasms

NCT06894511 2026-05-01

PSMAndARPI

Novartis

Phase 2 Active not recruiting
7 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT06449781 2025-02-10

PSMA-ADJUVO

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 2 Recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡